NAMS – newamsterdam pharma company n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an "outperform" rating on the stock.
Form SCHEDULE 13D/A NewAmsterdam Pharma Co Filed by: BCLS II Investco, LP
Form 144 NewAmsterdam Pharma Co Filed by: Bain Capital Life Sciences Fund II, L.P.
Form 144 NewAmsterdam Pharma Co Filed by: BCLS II Investco, LP
Form 144 NewAmsterdam Pharma Co Filed by: BCIP Life Sciences Associates, LP
Form SCHEDULE 13G/A NewAmsterdam Pharma Co Filed by: Capital World Investors
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.